Amgen EPO Patent Win Over Roche Could Derail Mircera Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
Boston jury finds Roche’s Mircera infringes Amgen’s erythropoietin patents and that all five Amgen patents are valid.
You may also be interested in...
Roche Appeals Mircera Injunction
Company seeks to overturn move barring anemia launch in the U.S.
Roche Appeals Mircera Injunction
Company seeks to overturn move barring anemia launch in the U.S.
Roche Agrees To Court Conditions For Mircera Launch
Roche says it will price Mircera at or below Epogen and pay Amgen a 22.5 percent royalty; Amgen presses for a permanent injunction against drug’s launch.